1 / 7

“Isolation of rare circulating tumour cells in cancer patients by microchip technology”

“Isolation of rare circulating tumour cells in cancer patients by microchip technology”. Nagrath et al. Nature 2007 Peter Bojo. Big Picture. Potential uses of CTCs Choice of therapy Monitoring of therapy Explaining the biology of metastasis Microchip is one of many CTC technologies

dewei
Download Presentation

“Isolation of rare circulating tumour cells in cancer patients by microchip technology”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Isolation of rare circulating tumour cells in cancerpatients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo

  2. Big Picture • Potential uses of CTCs • Choice of therapy • Monitoring of therapy • Explaining the biology of metastasis • Microchip is one of many CTC technologies • Immunomagnetic beads • Total RNA qPCR

  3. Microchip Design • Blood pumped through forest of posts • ~80,000 posts on a ~10cmX10cm chip • EpCAM antibodies on posts • Testing with cancer cell spiked solutions determines: • Flow rate ~1mL/hr • High capture efficiency even for low EpCAM expression levels ~60% • Identical capture efficiency for whole blood and lysed blood

  4. Microchip Workflow 1. Take whole blood sample, flow through optimized chip 2. Stain with DAPI, cytokeratin, and CD45 antibodies. 47% purity • Analyze CTC sensitivity, viability, • and predictive ability

  5. Cancer Patient CTC Experiment • NSCLC, prostate, pancreatic, breast, and colon cancer samples. • Metastatic and non-metastatic prostate cancer samples. • Isolated between 5 and 1300 CTCs per patient in 115/116 cases. • 0 CTCs in healthy samples • High sensitivity

  6. Predictive Ability for Cancer Treatment

  7. Conclusions • Microchip is a competitive CTC enrichment technology • Uses unprocessed blood • High purity of isolated cells: 47% • High sensitivity: 99% • Capture efficiency: ~60% • High cell viability: 98% • Further Study warranted for: • CTC count and tumor size correlation • Comparable numbers of CTCs in localized and metastatic cancers

More Related